Spaces:
Running
Running
File size: 72,139 Bytes
9754890 |
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 |
{
"cells": [
{
"cell_type": "code",
"execution_count": 44,
"metadata": {},
"outputs": [
{
"name": "stderr",
"output_type": "stream",
"text": [
"/Users/satoc/miniforge3/envs/gradio/lib/python3.12/site-packages/transformers/tokenization_utils_base.py:1617: FutureWarning: `clean_up_tokenization_spaces` was not set. It will be set to `True` by default. This behavior will be deprecated in transformers v4.45, and will be then set to `False` by default. For more details check this issue: https://github.com/huggingface/transformers/issues/31884\n",
" warnings.warn(\n"
]
}
],
"source": [
"from langchain_community.agent_toolkits import create_sql_agent\n",
"from langchain_openai import ChatOpenAI\n",
"from langchain_groq import ChatGroq\n",
"from langchain_core.prompts import ChatPromptTemplate\n",
"from langchain_core.pydantic_v1 import BaseModel, Field\n",
"import pandas as pd\n",
"from pydantic import BaseModel, Field\n",
"\n",
"from langchain.text_splitter import RecursiveCharacterTextSplitter\n",
"from langchain_community.vectorstores import Chroma\n",
"from langchain.embeddings import HuggingFaceEmbeddings\n",
"from langchain_core.runnables import RunnablePassthrough\n",
"from langchain_core.output_parsers import StrOutputParser\n",
"\n",
"\n",
"gpt = ChatOpenAI(model=\"gpt-3.5-turbo\", temperature=0)\n",
"#agent_gpt_executor = create_sql_agent(gpt, db=db, agent_type=\"tool-calling\", verbose=True)\n",
"\n",
"## make database\n",
"from langchain_community.utilities import SQLDatabase\n",
"from sqlalchemy import create_engine\n",
"\n",
"from langchain.prompts import ChatPromptTemplate\n",
"from langchain.schema import SystemMessage\n",
"from langchain_core.prompts import MessagesPlaceholder\n",
"#agent_groq_executor = create_sql_agent(llm, db=db, agent_type=\"tool-calling\", verbose=True)\n",
"\n",
"from OpenAITools.FetchTools import fetch_clinical_trials, fetch_clinical_trials_jp\n",
"from OpenAITools.CrinicalTrialTools import QuestionModifierEnglish, TumorNameExtractor, SimpleClinicalTrialAgent,GraderAgent,LLMTranslator,generate_ex_question_English\n",
"\n",
"from OpenAITools.JRCTTools import get_matched_df\n",
"from sentence_transformers import SentenceTransformer\n",
"from sentence_transformers import util\n",
"groq = ChatGroq(model_name=\"llama3-70b-8192\", temperature=0)\n",
"#agent_groq_executor = create_sql_agent(groq, db=db, agent_type=\"tool-calling\", verbose=True)\n",
"\n",
"import ast\n",
"import torch\n",
"age = \"65\"\n",
"sex =\"男性\"\n",
"tumor_type =\"glioma\"\n",
"#tumor_type = \"gastric cancer\"\n",
"GeneMutation =\"HER2\"\n",
"Meseable = \"有り\"\n",
"Biopsiable = \"有り\"\n",
"NCTID = 'NCT06441994'\n",
"\n",
"#Define extractor\n",
"Translator = LLMTranslator(groq)\n",
"TumorName = Translator.translate(tumor_type)\n",
"selectionModel = SentenceTransformer('pritamdeka/S-PubMedBert-MS-MARCO')\n",
"ex_question = generate_ex_question_English(age, sex, TumorName, GeneMutation, Meseable, Biopsiable)"
]
},
{
"cell_type": "code",
"execution_count": 45,
"metadata": {},
"outputs": [],
"source": [
"basedf = pd.read_csv(\"../ClinicalTrialCSV/JRCT20241215CancerPost.csv\", index_col=0)"
]
},
{
"cell_type": "code",
"execution_count": 46,
"metadata": {},
"outputs": [
{
"name": "stderr",
"output_type": "stream",
"text": [
"/var/folders/yw/qz00x75d7kb98f7vm8dkhkvw0000gn/T/ipykernel_49357/2492212482.py:2: SettingWithCopyWarning: \n",
"A value is trying to be set on a copy of a slice from a DataFrame.\n",
"Try using .loc[row_indexer,col_indexer] = value instead\n",
"\n",
"See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
" df['AgentJudgment'] = None\n",
"/var/folders/yw/qz00x75d7kb98f7vm8dkhkvw0000gn/T/ipykernel_49357/2492212482.py:3: SettingWithCopyWarning: \n",
"A value is trying to be set on a copy of a slice from a DataFrame.\n",
"Try using .loc[row_indexer,col_indexer] = value instead\n",
"\n",
"See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
" df['AgentGrade'] = None\n"
]
}
],
"source": [
"df = get_matched_df(basedf=basedf, query=TumorName, model=selectionModel, threshold=0.925)\n",
"df['AgentJudgment'] = None\n",
"df['AgentGrade'] = None"
]
},
{
"cell_type": "code",
"execution_count": 47,
"metadata": {},
"outputs": [
{
"data": {
"text/html": [
"<div>\n",
"<style scoped>\n",
" .dataframe tbody tr th:only-of-type {\n",
" vertical-align: middle;\n",
" }\n",
"\n",
" .dataframe tbody tr th {\n",
" vertical-align: top;\n",
" }\n",
"\n",
" .dataframe thead th {\n",
" text-align: right;\n",
" }\n",
"</style>\n",
"<table border=\"1\" class=\"dataframe\">\n",
" <thead>\n",
" <tr style=\"text-align: right;\">\n",
" <th></th>\n",
" <th>JRCT ID</th>\n",
" <th>NCT No</th>\n",
" <th>JapicCTI No</th>\n",
" <th>Title</th>\n",
" <th>TargetJ</th>\n",
" <th>Target</th>\n",
" <th>TargetEnglish</th>\n",
" <th>研究・治験の目的</th>\n",
" <th>試験等のフェーズ</th>\n",
" <th>試験の種類</th>\n",
" <th>...</th>\n",
" <th>Age Minimum</th>\n",
" <th>Age Maximum</th>\n",
" <th>Gender</th>\n",
" <th>Discontinuation Criteria</th>\n",
" <th>Keyword</th>\n",
" <th>Intervention(s)</th>\n",
" <th>TargetWord</th>\n",
" <th>TargetVec</th>\n",
" <th>AgentJudgment</th>\n",
" <th>AgentGrade</th>\n",
" </tr>\n",
" </thead>\n",
" <tbody>\n",
" <tr>\n",
" <th>82</th>\n",
" <td>jRCT2051240121</td>\n",
" <td>NCT06413706</td>\n",
" <td>NaN</td>\n",
" <td>放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ...</td>\n",
" <td>悪性神経膠腫</td>\n",
" <td>悪性神経膠腫</td>\n",
" <td>High-Grade Glioma</td>\n",
" <td>放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>No limit</td>\n",
" <td>21age old not</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Drug: Abemaciclib Administered orally Other Na...</td>\n",
" <td>['High-Grade Glioma']</td>\n",
" <td>[[-0.12244764715433121, -0.5778073668479919, -...</td>\n",
" <td>None</td>\n",
" <td>None</td>\n",
" </tr>\n",
" <tr>\n",
" <th>175</th>\n",
" <td>jRCT2031240090</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医...</td>\n",
" <td>悪性神経膠腫</td>\n",
" <td>悪性神経膠腫</td>\n",
" <td>Malignant glioma</td>\n",
" <td>再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis(N4-methyl...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>18age old over</td>\n",
" <td>75age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>glioblastoma, grade3/4 astrocytoma, grade3 oli...</td>\n",
" <td>Group A: BPC Therapy Depending on the patient'...</td>\n",
" <td>['Malignant Glioma']</td>\n",
" <td>[[-0.33767956495285034, -0.4648125171661377, -...</td>\n",
" <td>None</td>\n",
" <td>None</td>\n",
" </tr>\n",
" <tr>\n",
" <th>263</th>\n",
" <td>jRCT2041230136</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>再発膠芽腫に対するTUG1を標的とした核酸医薬医師主導第I相試験</td>\n",
" <td>再発膠芽腫</td>\n",
" <td>再発膠芽腫</td>\n",
" <td>recurrent glioblastoma</td>\n",
" <td>再発膠芽腫患者を対象としてTUG1ASOを投与した場合の投与時の安全性を検討し、至適投与量を...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>18age old over</td>\n",
" <td>75age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Dosing frequency: 1 time /week Dose Levels Lev...</td>\n",
" <td>['Recurrent', 'Glioblastoma']</td>\n",
" <td>[[-0.27501848340034485, -0.5264514088630676, -...</td>\n",
" <td>None</td>\n",
" <td>None</td>\n",
" </tr>\n",
" <tr>\n",
" <th>361</th>\n",
" <td>jRCT2051230069</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...</td>\n",
" <td>神経膠腫</td>\n",
" <td>神経膠腫</td>\n",
" <td>Glioma</td>\n",
" <td>神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併用療法の安全...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td><cohort1> Lomustine 130 mg/m2 orally every 6 w...</td>\n",
" <td>['Glioma']</td>\n",
" <td>[[-0.21631155908107758, -0.5687925219535828, -...</td>\n",
" <td>None</td>\n",
" <td>None</td>\n",
" </tr>\n",
" <tr>\n",
" <th>414</th>\n",
" <td>jRCT2031230007</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医...</td>\n",
" <td>低悪性度神経膠腫、膵癌</td>\n",
" <td>低悪性度神経膠腫、膵癌</td>\n",
" <td>Low-grade glioma, pancreatic cancer</td>\n",
" <td>BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫(コホート A...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>12age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>BRAF fusion gene, BRAF rearrangement, low-grad...</td>\n",
" <td>Binimetinib is administered 45 mg orally, twic...</td>\n",
" <td>['Low-Grade Glioma', 'Pancreatic Cancer']</td>\n",
" <td>[[-0.18604964017868042, -0.547483503818512, -0...</td>\n",
" <td>None</td>\n",
" <td>None</td>\n",
" </tr>\n",
" <tr>\n",
" <th>636</th>\n",
" <td>jRCT2031210299</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験</td>\n",
" <td>再発悪性神経膠腫</td>\n",
" <td>再発悪性神経膠腫</td>\n",
" <td>Recurrent High-Grade Glioma</td>\n",
" <td>再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Patients will receive DSP-0390 orally once dai...</td>\n",
" <td>['Recurrent', 'High-Grade Glioma']</td>\n",
" <td>[[-0.2750183045864105, -0.5264511704444885, -0...</td>\n",
" <td>None</td>\n",
" <td>None</td>\n",
" </tr>\n",
" <tr>\n",
" <th>712</th>\n",
" <td>jRCT2031200153</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Cellm-001による初発膠芽腫治療効果無作為比較対照試験</td>\n",
" <td>膠芽腫</td>\n",
" <td>膠芽腫</td>\n",
" <td>glioblastoma</td>\n",
" <td>脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>18age old over</td>\n",
" <td>75age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Inject the investigational drug (Cellm-001 or ...</td>\n",
" <td>['Glioblastoma']</td>\n",
" <td>[[-0.15113382041454315, -0.5002245306968689, -...</td>\n",
" <td>None</td>\n",
" <td>None</td>\n",
" </tr>\n",
" </tbody>\n",
"</table>\n",
"<p>7 rows × 43 columns</p>\n",
"</div>"
],
"text/plain": [
" JRCT ID NCT No JapicCTI No \\\n",
"82 jRCT2051240121 NCT06413706 NaN \n",
"175 jRCT2031240090 NaN NaN \n",
"263 jRCT2041230136 NaN NaN \n",
"361 jRCT2051230069 NaN NaN \n",
"414 jRCT2031230007 NaN NaN \n",
"636 jRCT2031210299 NaN NaN \n",
"712 jRCT2031200153 NaN NaN \n",
"\n",
" Title TargetJ \\\n",
"82 放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ... 悪性神経膠腫 \n",
"175 再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医... 悪性神経膠腫 \n",
"263 再発膠芽腫に対するTUG1を標的とした核酸医薬医師主導第I相試験 再発膠芽腫 \n",
"361 神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... 神経膠腫 \n",
"414 BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医... 低悪性度神経膠腫、膵癌 \n",
"636 再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験 再発悪性神経膠腫 \n",
"712 Cellm-001による初発膠芽腫治療効果無作為比較対照試験 膠芽腫 \n",
"\n",
" Target TargetEnglish \\\n",
"82 悪性神経膠腫 High-Grade Glioma \n",
"175 悪性神経膠腫 Malignant glioma \n",
"263 再発膠芽腫 recurrent glioblastoma \n",
"361 神経膠腫 Glioma \n",
"414 低悪性度神経膠腫、膵癌 Low-grade glioma, pancreatic cancer \n",
"636 再発悪性神経膠腫 Recurrent High-Grade Glioma \n",
"712 膠芽腫 glioblastoma \n",
"\n",
" 研究・治験の目的 試験等のフェーズ 試験の種類 ... \\\n",
"82 放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの... 2 NaN ... \n",
"175 再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis(N4-methyl... 3 NaN ... \n",
"263 再発膠芽腫患者を対象としてTUG1ASOを投与した場合の投与時の安全性を検討し、至適投与量を... 1 NaN ... \n",
"361 神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併用療法の安全... 1 NaN ... \n",
"414 BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫(コホート A... 2 NaN ... \n",
"636 再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び... 1 NaN ... \n",
"712 脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術... 3 NaN ... \n",
"\n",
" Age Minimum Age Maximum Gender Discontinuation Criteria \\\n",
"82 No limit 21age old not NaN NaN \n",
"175 18age old over 75age old under Both NaN \n",
"263 18age old over 75age old under Both NaN \n",
"361 18age old over No limit Both NaN \n",
"414 12age old over No limit Both NaN \n",
"636 18age old over No limit Both NaN \n",
"712 18age old over 75age old under Both NaN \n",
"\n",
" Keyword \\\n",
"82 NaN \n",
"175 glioblastoma, grade3/4 astrocytoma, grade3 oli... \n",
"263 NaN \n",
"361 NaN \n",
"414 BRAF fusion gene, BRAF rearrangement, low-grad... \n",
"636 NaN \n",
"712 NaN \n",
"\n",
" Intervention(s) \\\n",
"82 Drug: Abemaciclib Administered orally Other Na... \n",
"175 Group A: BPC Therapy Depending on the patient'... \n",
"263 Dosing frequency: 1 time /week Dose Levels Lev... \n",
"361 <cohort1> Lomustine 130 mg/m2 orally every 6 w... \n",
"414 Binimetinib is administered 45 mg orally, twic... \n",
"636 Patients will receive DSP-0390 orally once dai... \n",
"712 Inject the investigational drug (Cellm-001 or ... \n",
"\n",
" TargetWord \\\n",
"82 ['High-Grade Glioma'] \n",
"175 ['Malignant Glioma'] \n",
"263 ['Recurrent', 'Glioblastoma'] \n",
"361 ['Glioma'] \n",
"414 ['Low-Grade Glioma', 'Pancreatic Cancer'] \n",
"636 ['Recurrent', 'High-Grade Glioma'] \n",
"712 ['Glioblastoma'] \n",
"\n",
" TargetVec AgentJudgment \\\n",
"82 [[-0.12244764715433121, -0.5778073668479919, -... None \n",
"175 [[-0.33767956495285034, -0.4648125171661377, -... None \n",
"263 [[-0.27501848340034485, -0.5264514088630676, -... None \n",
"361 [[-0.21631155908107758, -0.5687925219535828, -... None \n",
"414 [[-0.18604964017868042, -0.547483503818512, -0... None \n",
"636 [[-0.2750183045864105, -0.5264511704444885, -0... None \n",
"712 [[-0.15113382041454315, -0.5002245306968689, -... None \n",
"\n",
" AgentGrade \n",
"82 None \n",
"175 None \n",
"263 None \n",
"361 None \n",
"414 None \n",
"636 None \n",
"712 None \n",
"\n",
"[7 rows x 43 columns]"
]
},
"execution_count": 47,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"df"
]
},
{
"cell_type": "code",
"execution_count": 48,
"metadata": {},
"outputs": [
{
"name": "stderr",
"output_type": "stream",
"text": [
"/var/folders/yw/qz00x75d7kb98f7vm8dkhkvw0000gn/T/ipykernel_49357/1375088122.py:1: SettingWithCopyWarning: \n",
"A value is trying to be set on a copy of a slice from a DataFrame.\n",
"Try using .loc[row_indexer,col_indexer] = value instead\n",
"\n",
"See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
" df['AgentJudgment'] = None\n",
"/var/folders/yw/qz00x75d7kb98f7vm8dkhkvw0000gn/T/ipykernel_49357/1375088122.py:2: SettingWithCopyWarning: \n",
"A value is trying to be set on a copy of a slice from a DataFrame.\n",
"Try using .loc[row_indexer,col_indexer] = value instead\n",
"\n",
"See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
" df['AgentGrade'] = None\n"
]
}
],
"source": [
"\n",
"df['AgentJudgment'] = None\n",
"df['AgentGrade'] = None\n",
"\n",
"#Define agents\n",
"#modifier = QuestionModifierEnglish(groq)\n",
"CriteriaCheckAgent = SimpleClinicalTrialAgent(groq)\n",
"grader_agent = GraderAgent(groq)"
]
},
{
"cell_type": "code",
"execution_count": 49,
"metadata": {},
"outputs": [
{
"data": {
"text/plain": [
"'Patients who meets any of the following criteria cannot participate in this clinical trial. -Diffuse Intrinsic Pontine Glioma (DIPG) or diffuse midline glioma located in the ? -Recurrent or refractory HGG including any recurrence/progression during/after radiotherapy. -Secondary HGG, defined as a previously treated low-grade glioma that now meets high- grade criteria, or that resulted from a previously treated malignancy. -Have known pathogenic somatic mutations appropriate for an anaplastic lymphoma kinase (ALK), B-rapidly accelerated fibrosarcoma (BRAF), or neurotrophic tyrosine receptor kinase (NTRK ) inhibitor, in regions where these therapies are available and deemed appropriate by the investigator. -Prior HGG treatment (including bevacizumab), except for surgery and radiotherapy (with or without concomitant temozolomide) -Current enrollment in another trial deemed. -Treatment with an investigational product within the last 30 days or 5 half-lives (whichever is longer). -Prior malignancy within the previous 3 years that, per the investigator and the medical monitor, may affect interpretation of study results. -A preexisting medical condition(s) that, per the investigator, would preclude study participation. -Any serious, active, systemic infection requiring IV antibiotic, antifungal, or antiviral therapy, including acute hepatitis B or C, or Human Immunodeficiency Virus at C1D1. -Intolerability or hypersensitivity such as urticaria, anaphylaxis, toxic necrolysis, and/or Stevens-Johnson syndrome, to temozolomide, its excipients, or dacarbazine. -Received a live virus vaccine within 28 days of C1D1. -Pregnant, breastfeeding, or intend to become pregnant during the study.'"
]
},
"execution_count": 49,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"df.iloc[0,:]['Inclusion Criteria']\n",
"df.iloc[0,:]['Exclusion Criteria']"
]
},
{
"cell_type": "code",
"execution_count": 50,
"metadata": {},
"outputs": [],
"source": [
"def GetJRCTCriteria(dataframe, idx):\n",
" InC = dataframe.iloc[idx,:]['Inclusion Criteria']\n",
" ExC = dataframe.iloc[idx,:]['Exclusion Criteria']\n",
" return \"Inclusion Criteria :\" + InC + \"\\n\" + \"Exclusion Criteria :\" + ExC"
]
},
{
"cell_type": "code",
"execution_count": 51,
"metadata": {},
"outputs": [],
"source": [
"TargetCriteria = GetJRCTCriteria(df,0)"
]
},
{
"cell_type": "code",
"execution_count": 52,
"metadata": {},
"outputs": [
{
"name": "stdout",
"output_type": "stream",
"text": [
"The patient is eligible for this clinical trial based on the provided information, as there are no exclusion criteria that would prevent him from participating.\n"
]
}
],
"source": [
"AgentJudgment = CriteriaCheckAgent.evaluate_eligibility(TargetCriteria, ex_question)\n",
"print(AgentJudgment)"
]
},
{
"cell_type": "code",
"execution_count": 53,
"metadata": {},
"outputs": [],
"source": [
"AgentGrade = grader_agent.evaluate_eligibility(AgentJudgment)"
]
},
{
"cell_type": "code",
"execution_count": 54,
"metadata": {},
"outputs": [
{
"data": {
"text/plain": [
"'yes'"
]
},
"execution_count": 54,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"AgentGrade"
]
},
{
"cell_type": "code",
"execution_count": 55,
"metadata": {},
"outputs": [],
"source": [
"ex_question = generate_ex_question_English(age, sex, TumorName, GeneMutation, Meseable, Biopsiable)"
]
},
{
"cell_type": "code",
"execution_count": 56,
"metadata": {},
"outputs": [
{
"name": "stdout",
"output_type": "stream",
"text": [
"The patient is eligible for this clinical trial based on the provided information, as there are no exclusion criteria that would prevent him from participating.\n",
"yes\n",
"The patient is eligible for this clinical trial based on the provided information, as the patient meets the inclusion criteria (age, measurable and biopsiable tumor, and no exclusion criteria mentioned).\n",
"yes\n",
"The patient is not eligible for this clinical trial because the patient's age (65) exceeds the upper limit of 75 years old specified in inclusion criterion (7).\n",
"no\n",
"Based on the provided information, the patient is eligible for this clinical trial. The patient meets the inclusion criteria for Cohort 1, as they have a glioma (WHO Grade 2-4) diagnosed by pathological diagnosis of resection or biopsy, have a history of chemotherapy or radiation therapy, and have measurable lesions based on the RANO criteria. The patient's age of 65 meets the age requirement, and there is no mention of any exclusion criteria that would prevent the patient from participating.\n",
"yes\n",
"The patient is not eligible for this clinical trial because the inclusion criteria specify that patients must have a BRAF fusion or rearrangement, but the patient has a HER2 gene mutation.\n",
"no\n",
"Based on the provided criteria, the 65-year-old male patient with glioma appears to be eligible for this clinical trial, as there are no specific age restrictions or exclusions mentioned. However, I do not know if the patient meets the other inclusion criteria, such as Karnofsky Performance Status (KPS) score, adequate organ function, and recovery from prior therapy, as this information is not provided.\n",
"unclear\n",
"The patient is eligible for this clinical trial based on the provided information, as the patient meets the inclusion criteria (age, measurable tumor, biopsiable tumor) and does not have any obvious exclusions (e.g., no mention of corticosteroids, immunosuppressive agents, or other exclusion criteria). However, some information is missing, such as Karnofsky Performance Status, neutrophil count, hemoglobin, platelet count, and other lab values, which would need to be confirmed to ensure full eligibility.\n",
"unclear\n"
]
}
],
"source": [
"for i in range(len(df)):\n",
" TargetCriteria = GetJRCTCriteria(df, i)\n",
" AgentJudgment = CriteriaCheckAgent.evaluate_eligibility(TargetCriteria, ex_question)\n",
" print(AgentJudgment)\n",
" AgentGrade = grader_agent.evaluate_eligibility(AgentJudgment)\n",
" print(AgentGrade)\n",
" \n",
" # df.locを使って値を代入（行・列名で指定）\n",
" df.loc[df.index[i], 'AgentJudgment'] = AgentJudgment\n",
" df.loc[df.index[i], 'AgentGrade'] = AgentGrade\n"
]
},
{
"cell_type": "markdown",
"metadata": {},
"source": [
"for i in range(len(df)):\n",
" TargetCriteria = GetJRCTCriteria(df,i)\n",
" AgentJudgment = CriteriaCheckAgent.evaluate_eligibility(TargetCriteria, ex_question)\n",
" print(AgentJudgment)\n",
" AgentGrade = grader_agent.evaluate_eligibility(AgentJudgment)\n",
" print(AgentGrade)\n",
" df.iloc[i,:]['AgentJudgment'] = AgentJudgment\n",
" df.iloc[i,:]['AgentJudgment'] = AgentGrade\n"
]
},
{
"cell_type": "markdown",
"metadata": {},
"source": []
},
{
"cell_type": "code",
"execution_count": 58,
"metadata": {},
"outputs": [
{
"data": {
"text/html": [
"<div>\n",
"<style scoped>\n",
" .dataframe tbody tr th:only-of-type {\n",
" vertical-align: middle;\n",
" }\n",
"\n",
" .dataframe tbody tr th {\n",
" vertical-align: top;\n",
" }\n",
"\n",
" .dataframe thead th {\n",
" text-align: right;\n",
" }\n",
"</style>\n",
"<table border=\"1\" class=\"dataframe\">\n",
" <thead>\n",
" <tr style=\"text-align: right;\">\n",
" <th></th>\n",
" <th>JRCT ID</th>\n",
" <th>NCT No</th>\n",
" <th>JapicCTI No</th>\n",
" <th>Title</th>\n",
" <th>TargetJ</th>\n",
" <th>Target</th>\n",
" <th>TargetEnglish</th>\n",
" <th>研究・治験の目的</th>\n",
" <th>試験等のフェーズ</th>\n",
" <th>試験の種類</th>\n",
" <th>...</th>\n",
" <th>Age Minimum</th>\n",
" <th>Age Maximum</th>\n",
" <th>Gender</th>\n",
" <th>Discontinuation Criteria</th>\n",
" <th>Keyword</th>\n",
" <th>Intervention(s)</th>\n",
" <th>TargetWord</th>\n",
" <th>TargetVec</th>\n",
" <th>AgentJudgment</th>\n",
" <th>AgentGrade</th>\n",
" </tr>\n",
" </thead>\n",
" <tbody>\n",
" <tr>\n",
" <th>82</th>\n",
" <td>jRCT2051240121</td>\n",
" <td>NCT06413706</td>\n",
" <td>NaN</td>\n",
" <td>放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ...</td>\n",
" <td>悪性神経膠腫</td>\n",
" <td>悪性神経膠腫</td>\n",
" <td>High-Grade Glioma</td>\n",
" <td>放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>No limit</td>\n",
" <td>21age old not</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Drug: Abemaciclib Administered orally Other Na...</td>\n",
" <td>['High-Grade Glioma']</td>\n",
" <td>[[-0.12244764715433121, -0.5778073668479919, -...</td>\n",
" <td>The patient is eligible for this clinical tria...</td>\n",
" <td>yes</td>\n",
" </tr>\n",
" <tr>\n",
" <th>175</th>\n",
" <td>jRCT2031240090</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医...</td>\n",
" <td>悪性神経膠腫</td>\n",
" <td>悪性神経膠腫</td>\n",
" <td>Malignant glioma</td>\n",
" <td>再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis(N4-methyl...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>18age old over</td>\n",
" <td>75age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>glioblastoma, grade3/4 astrocytoma, grade3 oli...</td>\n",
" <td>Group A: BPC Therapy Depending on the patient'...</td>\n",
" <td>['Malignant Glioma']</td>\n",
" <td>[[-0.33767956495285034, -0.4648125171661377, -...</td>\n",
" <td>The patient is eligible for this clinical tria...</td>\n",
" <td>yes</td>\n",
" </tr>\n",
" <tr>\n",
" <th>263</th>\n",
" <td>jRCT2041230136</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>再発膠芽腫に対するTUG1を標的とした核酸医薬医師主導第I相試験</td>\n",
" <td>再発膠芽腫</td>\n",
" <td>再発膠芽腫</td>\n",
" <td>recurrent glioblastoma</td>\n",
" <td>再発膠芽腫患者を対象としてTUG1ASOを投与した場合の投与時の安全性を検討し、至適投与量を...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>18age old over</td>\n",
" <td>75age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Dosing frequency: 1 time /week Dose Levels Lev...</td>\n",
" <td>['Recurrent', 'Glioblastoma']</td>\n",
" <td>[[-0.27501848340034485, -0.5264514088630676, -...</td>\n",
" <td>The patient is not eligible for this clinical ...</td>\n",
" <td>no</td>\n",
" </tr>\n",
" <tr>\n",
" <th>361</th>\n",
" <td>jRCT2051230069</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...</td>\n",
" <td>神経膠腫</td>\n",
" <td>神経膠腫</td>\n",
" <td>Glioma</td>\n",
" <td>神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併用療法の安全...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td><cohort1> Lomustine 130 mg/m2 orally every 6 w...</td>\n",
" <td>['Glioma']</td>\n",
" <td>[[-0.21631155908107758, -0.5687925219535828, -...</td>\n",
" <td>Based on the provided information, the patient...</td>\n",
" <td>yes</td>\n",
" </tr>\n",
" <tr>\n",
" <th>414</th>\n",
" <td>jRCT2031230007</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医...</td>\n",
" <td>低悪性度神経膠腫、膵癌</td>\n",
" <td>低悪性度神経膠腫、膵癌</td>\n",
" <td>Low-grade glioma, pancreatic cancer</td>\n",
" <td>BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫(コホート A...</td>\n",
" <td>2</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>12age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>BRAF fusion gene, BRAF rearrangement, low-grad...</td>\n",
" <td>Binimetinib is administered 45 mg orally, twic...</td>\n",
" <td>['Low-Grade Glioma', 'Pancreatic Cancer']</td>\n",
" <td>[[-0.18604964017868042, -0.547483503818512, -0...</td>\n",
" <td>The patient is not eligible for this clinical ...</td>\n",
" <td>no</td>\n",
" </tr>\n",
" <tr>\n",
" <th>636</th>\n",
" <td>jRCT2031210299</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験</td>\n",
" <td>再発悪性神経膠腫</td>\n",
" <td>再発悪性神経膠腫</td>\n",
" <td>Recurrent High-Grade Glioma</td>\n",
" <td>再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び...</td>\n",
" <td>1</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>18age old over</td>\n",
" <td>No limit</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Patients will receive DSP-0390 orally once dai...</td>\n",
" <td>['Recurrent', 'High-Grade Glioma']</td>\n",
" <td>[[-0.2750183045864105, -0.5264511704444885, -0...</td>\n",
" <td>Based on the provided criteria, the 65-year-ol...</td>\n",
" <td>unclear</td>\n",
" </tr>\n",
" <tr>\n",
" <th>712</th>\n",
" <td>jRCT2031200153</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Cellm-001による初発膠芽腫治療効果無作為比較対照試験</td>\n",
" <td>膠芽腫</td>\n",
" <td>膠芽腫</td>\n",
" <td>glioblastoma</td>\n",
" <td>脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術...</td>\n",
" <td>3</td>\n",
" <td>NaN</td>\n",
" <td>...</td>\n",
" <td>18age old over</td>\n",
" <td>75age old under</td>\n",
" <td>Both</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" <td>Inject the investigational drug (Cellm-001 or ...</td>\n",
" <td>['Glioblastoma']</td>\n",
" <td>[[-0.15113382041454315, -0.5002245306968689, -...</td>\n",
" <td>The patient is eligible for this clinical tria...</td>\n",
" <td>unclear</td>\n",
" </tr>\n",
" </tbody>\n",
"</table>\n",
"<p>7 rows × 43 columns</p>\n",
"</div>"
],
"text/plain": [
" JRCT ID NCT No JapicCTI No \\\n",
"82 jRCT2051240121 NCT06413706 NaN \n",
"175 jRCT2031240090 NaN NaN \n",
"263 jRCT2041230136 NaN NaN \n",
"361 jRCT2051230069 NaN NaN \n",
"414 jRCT2031230007 NaN NaN \n",
"636 jRCT2031210299 NaN NaN \n",
"712 jRCT2031200153 NaN NaN \n",
"\n",
" Title TargetJ \\\n",
"82 放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ... 悪性神経膠腫 \n",
"175 再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医... 悪性神経膠腫 \n",
"263 再発膠芽腫に対するTUG1を標的とした核酸医薬医師主導第I相試験 再発膠芽腫 \n",
"361 神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... 神経膠腫 \n",
"414 BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医... 低悪性度神経膠腫、膵癌 \n",
"636 再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験 再発悪性神経膠腫 \n",
"712 Cellm-001による初発膠芽腫治療効果無作為比較対照試験 膠芽腫 \n",
"\n",
" Target TargetEnglish \\\n",
"82 悪性神経膠腫 High-Grade Glioma \n",
"175 悪性神経膠腫 Malignant glioma \n",
"263 再発膠芽腫 recurrent glioblastoma \n",
"361 神経膠腫 Glioma \n",
"414 低悪性度神経膠腫、膵癌 Low-grade glioma, pancreatic cancer \n",
"636 再発悪性神経膠腫 Recurrent High-Grade Glioma \n",
"712 膠芽腫 glioblastoma \n",
"\n",
" 研究・治験の目的 試験等のフェーズ 試験の種類 ... \\\n",
"82 放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの... 2 NaN ... \n",
"175 再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis(N4-methyl... 3 NaN ... \n",
"263 再発膠芽腫患者を対象としてTUG1ASOを投与した場合の投与時の安全性を検討し、至適投与量を... 1 NaN ... \n",
"361 神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併用療法の安全... 1 NaN ... \n",
"414 BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫(コホート A... 2 NaN ... \n",
"636 再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び... 1 NaN ... \n",
"712 脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術... 3 NaN ... \n",
"\n",
" Age Minimum Age Maximum Gender Discontinuation Criteria \\\n",
"82 No limit 21age old not NaN NaN \n",
"175 18age old over 75age old under Both NaN \n",
"263 18age old over 75age old under Both NaN \n",
"361 18age old over No limit Both NaN \n",
"414 12age old over No limit Both NaN \n",
"636 18age old over No limit Both NaN \n",
"712 18age old over 75age old under Both NaN \n",
"\n",
" Keyword \\\n",
"82 NaN \n",
"175 glioblastoma, grade3/4 astrocytoma, grade3 oli... \n",
"263 NaN \n",
"361 NaN \n",
"414 BRAF fusion gene, BRAF rearrangement, low-grad... \n",
"636 NaN \n",
"712 NaN \n",
"\n",
" Intervention(s) \\\n",
"82 Drug: Abemaciclib Administered orally Other Na... \n",
"175 Group A: BPC Therapy Depending on the patient'... \n",
"263 Dosing frequency: 1 time /week Dose Levels Lev... \n",
"361 <cohort1> Lomustine 130 mg/m2 orally every 6 w... \n",
"414 Binimetinib is administered 45 mg orally, twic... \n",
"636 Patients will receive DSP-0390 orally once dai... \n",
"712 Inject the investigational drug (Cellm-001 or ... \n",
"\n",
" TargetWord \\\n",
"82 ['High-Grade Glioma'] \n",
"175 ['Malignant Glioma'] \n",
"263 ['Recurrent', 'Glioblastoma'] \n",
"361 ['Glioma'] \n",
"414 ['Low-Grade Glioma', 'Pancreatic Cancer'] \n",
"636 ['Recurrent', 'High-Grade Glioma'] \n",
"712 ['Glioblastoma'] \n",
"\n",
" TargetVec \\\n",
"82 [[-0.12244764715433121, -0.5778073668479919, -... \n",
"175 [[-0.33767956495285034, -0.4648125171661377, -... \n",
"263 [[-0.27501848340034485, -0.5264514088630676, -... \n",
"361 [[-0.21631155908107758, -0.5687925219535828, -... \n",
"414 [[-0.18604964017868042, -0.547483503818512, -0... \n",
"636 [[-0.2750183045864105, -0.5264511704444885, -0... \n",
"712 [[-0.15113382041454315, -0.5002245306968689, -... \n",
"\n",
" AgentJudgment AgentGrade \n",
"82 The patient is eligible for this clinical tria... yes \n",
"175 The patient is eligible for this clinical tria... yes \n",
"263 The patient is not eligible for this clinical ... no \n",
"361 Based on the provided information, the patient... yes \n",
"414 The patient is not eligible for this clinical ... no \n",
"636 Based on the provided criteria, the 65-year-ol... unclear \n",
"712 The patient is eligible for this clinical tria... unclear \n",
"\n",
"[7 rows x 43 columns]"
]
},
"execution_count": 58,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"df"
]
},
{
"cell_type": "code",
"execution_count": 59,
"metadata": {},
"outputs": [
{
"data": {
"text/plain": [
"Index(['JRCT ID', 'NCT No', 'JapicCTI No', 'Title', 'TargetJ', 'Target',\n",
" 'TargetEnglish', '研究・治験の目的', '試験等のフェーズ', '試験の種類', '無作為化', '盲検化', '対照',\n",
" '割付け', '研究目的', '主たる選択基準', '主たる除外基準', '年齢下限', '年齢上限', '性別', '中止基準',\n",
" '対象疾患キーワード', '介入の内容', 'URL', 'Phase', 'Study Type', 'allocation',\n",
" 'masking', 'control', 'assignment', 'purpose', 'Inclusion Criteria',\n",
" 'Exclusion Criteria', 'Age Minimum', 'Age Maximum', 'Gender',\n",
" 'Discontinuation Criteria', 'Keyword', 'Intervention(s)', 'TargetWord',\n",
" 'TargetVec', 'AgentJudgment', 'AgentGrade'],\n",
" dtype='object')"
]
},
"execution_count": 59,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"df.columns"
]
},
{
"cell_type": "code",
"execution_count": 62,
"metadata": {},
"outputs": [],
"source": [
" # 列を指定した順に並び替え\n",
"columns_order = ['JRCT ID', 'Title', '研究・治験の目的','AgentJudgment', 'AgentGrade','主たる選択基準', '主たる除外基準','Inclusion Criteria','Exclusion Criteria','NCT No', 'JapicCTI No']\n",
"df = df[columns_order]"
]
},
{
"cell_type": "code",
"execution_count": 63,
"metadata": {},
"outputs": [
{
"data": {
"text/html": [
"<div>\n",
"<style scoped>\n",
" .dataframe tbody tr th:only-of-type {\n",
" vertical-align: middle;\n",
" }\n",
"\n",
" .dataframe tbody tr th {\n",
" vertical-align: top;\n",
" }\n",
"\n",
" .dataframe thead th {\n",
" text-align: right;\n",
" }\n",
"</style>\n",
"<table border=\"1\" class=\"dataframe\">\n",
" <thead>\n",
" <tr style=\"text-align: right;\">\n",
" <th></th>\n",
" <th>JRCT ID</th>\n",
" <th>Title</th>\n",
" <th>研究・治験の目的</th>\n",
" <th>AgentJudgment</th>\n",
" <th>AgentGrade</th>\n",
" <th>主たる選択基準</th>\n",
" <th>主たる除外基準</th>\n",
" <th>Inclusion Criteria</th>\n",
" <th>Exclusion Criteria</th>\n",
" <th>NCT No</th>\n",
" <th>JapicCTI No</th>\n",
" </tr>\n",
" </thead>\n",
" <tbody>\n",
" <tr>\n",
" <th>82</th>\n",
" <td>jRCT2051240121</td>\n",
" <td>放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ...</td>\n",
" <td>放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの...</td>\n",
" <td>The patient is eligible for this clinical tria...</td>\n",
" <td>yes</td>\n",
" <td>以下の基準をすべて満たす必要がある ‐生検によって、以下に示す2016 年WHO分類グレード...</td>\n",
" <td>以下の基準のいずれかに該当する場合、本治験へ参加できない。 ‐びまん性橋膠腫(diffuse...</td>\n",
" <td>Subjects required to meet all the folloiwng cr...</td>\n",
" <td>Patients who meets any of the following criter...</td>\n",
" <td>NCT06413706</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>175</th>\n",
" <td>jRCT2031240090</td>\n",
" <td>再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医...</td>\n",
" <td>再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis(N4-methyl...</td>\n",
" <td>The patient is eligible for this clinical tria...</td>\n",
" <td>yes</td>\n",
" <td>1) 登録前直近の病理診断により組織学的にWHO2021に基づく悪性神経膠腫(膠芽腫または、...</td>\n",
" <td>1) 登録前2年以内の他の悪性腫瘍の既往または合併を有する。ただし局所治療により治癒と判断さ...</td>\n",
" <td>1) Histologically diagnosed as high grade glio...</td>\n",
" <td>1) Have a history or merger of other malignanc...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>263</th>\n",
" <td>jRCT2041230136</td>\n",
" <td>再発膠芽腫に対するTUG1を標的とした核酸医薬医師主導第I相試験</td>\n",
" <td>再発膠芽腫患者を対象としてTUG1ASOを投与した場合の投与時の安全性を検討し、至適投与量を...</td>\n",
" <td>The patient is not eligible for this clinical ...</td>\n",
" <td>no</td>\n",
" <td>(1)手術摘出検体又は生検検体の永久標本にて、組織学的に膠芽腫と診断されている患者 (2)標...</td>\n",
" <td>(1)脳外転移のある患者 (2)著明な頭蓋内圧亢進症状のある患者 (3)初発時又は再発・増悪...</td>\n",
" <td>(1) Patients with a histological diagnosis of ...</td>\n",
" <td>(1) Patients with extracerebral metastases. (2...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>361</th>\n",
" <td>jRCT2051230069</td>\n",
" <td>神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全...</td>\n",
" <td>神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併用療法の安全...</td>\n",
" <td>Based on the provided information, the patient...</td>\n",
" <td>yes</td>\n",
" <td><コホート1>以下のすべての項目を満たすものとする。 1)摘出術又は生検の病理診断にて、神経...</td>\n",
" <td><コホート1、コホート2共通> 1) 活動性の重複がんを有する(同時性重複がん/多発がん及び...</td>\n",
" <td><Cohort 1> All of the following items shall be...</td>\n",
" <td><Common to Cohort 1 and Cohort 2> 1) Active mu...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>414</th>\n",
" <td>jRCT2031230007</td>\n",
" <td>BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医...</td>\n",
" <td>BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫(コホート A...</td>\n",
" <td>The patient is not eligible for this clinical ...</td>\n",
" <td>no</td>\n",
" <td>コホートA、コホートB共通の適格規準 1) 保険診療下で行われているNGSを用いたがん遺伝子...</td>\n",
" <td>1) 活動性の重複がんを有する(ただし、次の1~3は除外しない:1完全切除された以下のがん:...</td>\n",
" <td>Inclusion criteria for both cohort A and B 1) ...</td>\n",
" <td>1) Active double primary cancer (but not (1)-(...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>636</th>\n",
" <td>jRCT2031210299</td>\n",
" <td>再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験</td>\n",
" <td>再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び...</td>\n",
" <td>Based on the provided criteria, the 65-year-ol...</td>\n",
" <td>unclear</td>\n",
" <td>1. 3ヵ月以上の生存が見込める患者 2. 前治療(化学療法、手術又は放射線療法)による副作...</td>\n",
" <td>1. Day 1前の3ヵ月以内にベバシズマブ又はその他の血管内皮増殖因子(VEGF)阻害薬に...</td>\n",
" <td>1. Estimated life expectancy >= 3 months 2. Re...</td>\n",
" <td>1. Prior therapy with bevacizumab or other ant...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" <tr>\n",
" <th>712</th>\n",
" <td>jRCT2031200153</td>\n",
" <td>Cellm-001による初発膠芽腫治療効果無作為比較対照試験</td>\n",
" <td>脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術...</td>\n",
" <td>The patient is eligible for this clinical tria...</td>\n",
" <td>unclear</td>\n",
" <td>(1)年齢は満18歳以上、75歳以下である。 (2)テント上の膠芽腫(WHO Grade I...</td>\n",
" <td>(1)登録前14日以内の副腎皮質ステロイド剤(10mg/日超のプレドニゾロン、あるいは相当量...</td>\n",
" <td>(1) 18 years old or older and 75 years old or ...</td>\n",
" <td>(1) Systemic administration of corticosteroids...</td>\n",
" <td>NaN</td>\n",
" <td>NaN</td>\n",
" </tr>\n",
" </tbody>\n",
"</table>\n",
"</div>"
],
"text/plain": [
" JRCT ID Title \\\n",
"82 jRCT2051240121 放射線療法後の悪性神経膠腫の小児および若年成人を対象に、アベマシクリブ＋テモゾロミドとテモゾ... \n",
"175 jRCT2031240090 再発悪性神経膠腫に対する治療用放射性薬剤64Cu-ATSMの有効性を検証するランダム化比較医... \n",
"263 jRCT2041230136 再発膠芽腫に対するTUG1を標的とした核酸医薬医師主導第I相試験 \n",
"361 jRCT2051230069 神経膠腫患者に対するロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併⽤療法の安全... \n",
"414 jRCT2031230007 BRAF融合遺伝子陽性の進行・再発の低悪性度神経膠腫または膵癌に対するビニメチニブの第Ⅱ相医... \n",
"636 jRCT2031210299 再発悪性神経膠腫患者を対象としたDSP-0390の第1相試験 \n",
"712 jRCT2031200153 Cellm-001による初発膠芽腫治療効果無作為比較対照試験 \n",
"\n",
" 研究・治験の目的 \\\n",
"82 放射線療法後の悪性神経膠腫を有する小児および若年成人を対象に、アベマシクリブとテモゾロミドの... \n",
"175 再発・難治性悪性神経膠腫を対象として、64Cu-diacetyl-bis(N4-methyl... \n",
"263 再発膠芽腫患者を対象としてTUG1ASOを投与した場合の投与時の安全性を検討し、至適投与量を... \n",
"361 神経膠腫患者におけるロムスチン療法とプロカルバジン、ロムスチン、ビンクリスチン併用療法の安全... \n",
"414 BRAF融合遺伝子または遺伝子再構成陽性の切除不能または再発の低悪性度神経膠腫(コホート A... \n",
"636 再発悪性神経膠腫患者を対象にDSP-0390を経口投与したときの安全性、薬物動態、薬力学及び... \n",
"712 脳腫瘍のうち、初発悪性膠芽腫に対する自家脳腫瘍免疫賦活剤であるCellm-001について、術... \n",
"\n",
" AgentJudgment AgentGrade \\\n",
"82 The patient is eligible for this clinical tria... yes \n",
"175 The patient is eligible for this clinical tria... yes \n",
"263 The patient is not eligible for this clinical ... no \n",
"361 Based on the provided information, the patient... yes \n",
"414 The patient is not eligible for this clinical ... no \n",
"636 Based on the provided criteria, the 65-year-ol... unclear \n",
"712 The patient is eligible for this clinical tria... unclear \n",
"\n",
" 主たる選択基準 \\\n",
"82 以下の基準をすべて満たす必要がある ‐生検によって、以下に示す2016 年WHO分類グレード... \n",
"175 1) 登録前直近の病理診断により組織学的にWHO2021に基づく悪性神経膠腫(膠芽腫または、... \n",
"263 (1)手術摘出検体又は生検検体の永久標本にて、組織学的に膠芽腫と診断されている患者 (2)標... \n",
"361 <コホート1>以下のすべての項目を満たすものとする。 1)摘出術又は生検の病理診断にて、神経... \n",
"414 コホートA、コホートB共通の適格規準 1) 保険診療下で行われているNGSを用いたがん遺伝子... \n",
"636 1. 3ヵ月以上の生存が見込める患者 2. 前治療(化学療法、手術又は放射線療法)による副作... \n",
"712 (1)年齢は満18歳以上、75歳以下である。 (2)テント上の膠芽腫(WHO Grade I... \n",
"\n",
" 主たる除外基準 \\\n",
"82 以下の基準のいずれかに該当する場合、本治験へ参加できない。 ‐びまん性橋膠腫(diffuse... \n",
"175 1) 登録前2年以内の他の悪性腫瘍の既往または合併を有する。ただし局所治療により治癒と判断さ... \n",
"263 (1)脳外転移のある患者 (2)著明な頭蓋内圧亢進症状のある患者 (3)初発時又は再発・増悪... \n",
"361 <コホート1、コホート2共通> 1) 活動性の重複がんを有する(同時性重複がん/多発がん及び... \n",
"414 1) 活動性の重複がんを有する(ただし、次の1~3は除外しない:1完全切除された以下のがん:... \n",
"636 1. Day 1前の3ヵ月以内にベバシズマブ又はその他の血管内皮増殖因子(VEGF)阻害薬に... \n",
"712 (1)登録前14日以内の副腎皮質ステロイド剤(10mg/日超のプレドニゾロン、あるいは相当量... \n",
"\n",
" Inclusion Criteria \\\n",
"82 Subjects required to meet all the folloiwng cr... \n",
"175 1) Histologically diagnosed as high grade glio... \n",
"263 (1) Patients with a histological diagnosis of ... \n",
"361 <Cohort 1> All of the following items shall be... \n",
"414 Inclusion criteria for both cohort A and B 1) ... \n",
"636 1. Estimated life expectancy >= 3 months 2. Re... \n",
"712 (1) 18 years old or older and 75 years old or ... \n",
"\n",
" Exclusion Criteria NCT No \\\n",
"82 Patients who meets any of the following criter... NCT06413706 \n",
"175 1) Have a history or merger of other malignanc... NaN \n",
"263 (1) Patients with extracerebral metastases. (2... NaN \n",
"361 <Common to Cohort 1 and Cohort 2> 1) Active mu... NaN \n",
"414 1) Active double primary cancer (but not (1)-(... NaN \n",
"636 1. Prior therapy with bevacizumab or other ant... NaN \n",
"712 (1) Systemic administration of corticosteroids... NaN \n",
"\n",
" JapicCTI No \n",
"82 NaN \n",
"175 NaN \n",
"263 NaN \n",
"361 NaN \n",
"414 NaN \n",
"636 NaN \n",
"712 NaN "
]
},
"execution_count": 63,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"df"
]
},
{
"cell_type": "code",
"execution_count": 5,
"metadata": {},
"outputs": [],
"source": [
" # 列を指定した順に並び替え\n",
"columns_order = ['NCTID', 'AgentGrade', 'Title', 'AgentJudgment', 'Japanes Locations', \n",
" 'Primary Completion Date', 'Cancer', 'Summary', 'Eligibility Criteria']\n",
"df = df[columns_order] "
]
},
{
"cell_type": "code",
"execution_count": 6,
"metadata": {},
"outputs": [
{
"data": {
"text/html": [
"<div>\n",
"<style scoped>\n",
" .dataframe tbody tr th:only-of-type {\n",
" vertical-align: middle;\n",
" }\n",
"\n",
" .dataframe tbody tr th {\n",
" vertical-align: top;\n",
" }\n",
"\n",
" .dataframe thead th {\n",
" text-align: right;\n",
" }\n",
"</style>\n",
"<table border=\"1\" class=\"dataframe\">\n",
" <thead>\n",
" <tr style=\"text-align: right;\">\n",
" <th></th>\n",
" <th>NCTID</th>\n",
" <th>AgentGrade</th>\n",
" <th>Title</th>\n",
" <th>AgentJudgment</th>\n",
" <th>Japanes Locations</th>\n",
" <th>Primary Completion Date</th>\n",
" <th>Cancer</th>\n",
" <th>Summary</th>\n",
" <th>Eligibility Criteria</th>\n",
" </tr>\n",
" </thead>\n",
" <tbody>\n",
" <tr>\n",
" <th>0</th>\n",
" <td>NCT05580562</td>\n",
" <td>no</td>\n",
" <td>ONC201 in H3 K27M-mutant Diffuse Glioma Follow...</td>\n",
" <td>The patient is not eligible for this clinical ...</td>\n",
" <td>Chuo City, Fukuoka, Kyoto, Osaka, Sapporo</td>\n",
" <td>2026-08</td>\n",
" <td>H3 K27M, Glioma</td>\n",
" <td>This is a randomized, double-blind, placebo-co...</td>\n",
" <td>Inclusion Criteria:\\n\\n1. Able to understand t...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>1</th>\n",
" <td>NCT06413706</td>\n",
" <td>yes</td>\n",
" <td>A Study Comparing Abemaciclib Plus Temozolomid...</td>\n",
" <td>The patient is eligible for this clinical tria...</td>\n",
" <td>Nagoya, Osaka, Tokyo</td>\n",
" <td>2027-07</td>\n",
" <td>Glioma</td>\n",
" <td>The purpose of this study is to measure the be...</td>\n",
" <td>Inclusion Criteria:\\n\\n* Biopsy proven high-gr...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>2</th>\n",
" <td>NCT05503264</td>\n",
" <td>no</td>\n",
" <td>A Study To Evaluate The Efficacy, Safety, Phar...</td>\n",
" <td>The patient is not eligible for this clinical ...</td>\n",
" <td>Aichi, Chiba, Fukuoka, Gifu, Hokkaido, Hyogo, ...</td>\n",
" <td>2026-06-23</td>\n",
" <td>NMDAR Autoimmune Encephalitis, LGI1 Autoimmune...</td>\n",
" <td>The purpose of this study is to assess the eff...</td>\n",
" <td>Inclusion Criteria:\\n\\n* Reasonable exclusion ...</td>\n",
" </tr>\n",
" <tr>\n",
" <th>3</th>\n",
" <td>NCT06159478</td>\n",
" <td>no</td>\n",
" <td>Binimetinib in Patients With BRAF Fusion-posit...</td>\n",
" <td>The patient is not eligible for this clinical ...</td>\n",
" <td>Fukuoka, Kashiwa, Kyoto City, Sapporo, Sendai, ku</td>\n",
" <td>2027-02-28</td>\n",
" <td>Low-grade Glioma, Pancreatic Cancer</td>\n",
" <td>This study is an open-label, parallel, 2-cohor...</td>\n",
" <td>Inclusion Criteria:\\n\\nInclusion criteria for ...</td>\n",
" </tr>\n",
" </tbody>\n",
"</table>\n",
"</div>"
],
"text/plain": [
" NCTID AgentGrade Title \\\n",
"0 NCT05580562 no ONC201 in H3 K27M-mutant Diffuse Glioma Follow... \n",
"1 NCT06413706 yes A Study Comparing Abemaciclib Plus Temozolomid... \n",
"2 NCT05503264 no A Study To Evaluate The Efficacy, Safety, Phar... \n",
"3 NCT06159478 no Binimetinib in Patients With BRAF Fusion-posit... \n",
"\n",
" AgentJudgment \\\n",
"0 The patient is not eligible for this clinical ... \n",
"1 The patient is eligible for this clinical tria... \n",
"2 The patient is not eligible for this clinical ... \n",
"3 The patient is not eligible for this clinical ... \n",
"\n",
" Japanes Locations Primary Completion Date \\\n",
"0 Chuo City, Fukuoka, Kyoto, Osaka, Sapporo 2026-08 \n",
"1 Nagoya, Osaka, Tokyo 2027-07 \n",
"2 Aichi, Chiba, Fukuoka, Gifu, Hokkaido, Hyogo, ... 2026-06-23 \n",
"3 Fukuoka, Kashiwa, Kyoto City, Sapporo, Sendai, ku 2027-02-28 \n",
"\n",
" Cancer \\\n",
"0 H3 K27M, Glioma \n",
"1 Glioma \n",
"2 NMDAR Autoimmune Encephalitis, LGI1 Autoimmune... \n",
"3 Low-grade Glioma, Pancreatic Cancer \n",
"\n",
" Summary \\\n",
"0 This is a randomized, double-blind, placebo-co... \n",
"1 The purpose of this study is to measure the be... \n",
"2 The purpose of this study is to assess the eff... \n",
"3 This study is an open-label, parallel, 2-cohor... \n",
"\n",
" Eligibility Criteria \n",
"0 Inclusion Criteria:\\n\\n1. Able to understand t... \n",
"1 Inclusion Criteria:\\n\\n* Biopsy proven high-gr... \n",
"2 Inclusion Criteria:\\n\\n* Reasonable exclusion ... \n",
"3 Inclusion Criteria:\\n\\nInclusion criteria for ... "
]
},
"execution_count": 6,
"metadata": {},
"output_type": "execute_result"
}
],
"source": [
"df"
]
},
{
"cell_type": "code",
"execution_count": null,
"metadata": {},
"outputs": [],
"source": []
}
],
"metadata": {
"kernelspec": {
"display_name": "gradio",
"language": "python",
"name": "python3"
},
"language_info": {
"codemirror_mode": {
"name": "ipython",
"version": 3
},
"file_extension": ".py",
"mimetype": "text/x-python",
"name": "python",
"nbconvert_exporter": "python",
"pygments_lexer": "ipython3",
"version": "3.12.3"
}
},
"nbformat": 4,
"nbformat_minor": 2
}
|